| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0896-6273(91)90052-2 |
| P698 | PubMed publication ID | 1673054 |
| P2093 | author name string | Selkoe DJ | |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pathology | Q7208 |
| Alzheimer's disease | Q11081 | ||
| P304 | page(s) | 487-498 | |
| P577 | publication date | 1991-04-01 | |
| P1433 | published in | Neuron | Q3338676 |
| P1476 | title | The molecular pathology of Alzheimer's disease. | |
| P478 | volume | 6 |
| Q38441500 | "Boomerang Neuropathology" of Late-Onset Alzheimer's Disease is Shrouded in Harmful "BDDS": Breathing, Diet, Drinking, and Sleep During Aging |
| Q47547512 | 18F-FPYBF-2, a new F-18-labelled amyloid imaging PET tracer: first experience in 61 volunteers and 55 patients with dementia. |
| Q42795680 | A 109-amino-acid C-terminal fragment of Alzheimer's-disease amyloid precursor protein contains a sequence, -RHDS-, that promotes cell adhesion |
| Q45071385 | A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease |
| Q37688750 | A 2-process model for neuropathology of Alzheimer's disease |
| Q57371926 | A Novel γ-Secretase Assay Based on Detection of the Putative C-terminal Fragment-γ of Amyloid β Protein Precursor |
| Q47941386 | A biotechnological method provides access to aggregation competent monomeric Alzheimer's 1-42 residue amyloid peptide |
| Q57163793 | A brief overview of the Swi1 prion-[SWI+] |
| Q37430503 | A central role for dityrosine crosslinking of Amyloid-β in Alzheimer's disease. |
| Q43066105 | A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta |
| Q36430458 | A combination extract of ginseng, epimedium, polygala, and tuber curcumae increases synaptophysin expression in APPV717I transgenic mice |
| Q90893924 | A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease |
| Q34376103 | A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease |
| Q55322228 | A discrete mathematical model for the aggregation of β-Amyloid. |
| Q37242843 | A facile method for expression and purification of the Alzheimer's disease-associated amyloid beta-peptide |
| Q35156254 | A fast and reproducible method for albumin isolation and depletion from serum and cerebrospinal fluid. |
| Q54959405 | A guide to using functional magnetic resonance imaging to study Alzheimer's disease in animal models. |
| Q30411177 | A heme oxygenase-1 transducer model of degenerative and developmental brain disorders |
| Q53178841 | A locus for familial early-onset Alzheimer's disease on the long arm of chromosome 14, proximal to the alpha 1-antichymotrypsin gene. |
| Q58722978 | A mathematical model for the effects of amyloid beta on intracellular calcium |
| Q35166007 | A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease |
| Q35216697 | A monoclonal antibody against synthetic Aβ dimer assemblies neutralizes brain-derived synaptic plasticity-disrupting Aβ. |
| Q90140035 | A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia |
| Q40779597 | A new hypothesis for the mechanism of amyloid toxicity, based on the calcium channel activity of amyloid beta protein (A beta P) in phospholipid bilayer membranes |
| Q24312856 | A novel serine proteinase-like sequence from human brain |
| Q28207898 | A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid |
| Q46064935 | A role for synaptic zinc in activity-dependent Abeta oligomer formation and accumulation at excitatory synapses. |
| Q34786664 | A vaccine against Alzheimer's disease: developments to date |
| Q27318148 | AAV2/1 CD74 Gene Transfer Reduces β-amyloidosis and Improves Learning and Memory in a Mouse Model of Alzheimer's Disease. |
| Q36015561 | ACS chemical neuroscience molecule spotlight on BMS-708163. |
| Q42186836 | ACS chemical neuroscience molecule spotlight on Begacestat (GSI-953). |
| Q90580004 | AD "Statin": Alzheimer's Disorder is a "Fast" Disease Preventable by Therapeutic Intervention Initiated Even Late in Life and Reversible at the Early Stages |
| Q53358753 | AFM and STM study of beta-amyloid aggregation on graphite. |
| Q48891549 | APP carboxyl-terminal fragment without or with abeta domain equally induces cytotoxicity in differentiated PC12 cells and cortical neurons. |
| Q33816233 | ASIP Outstanding Investigator Award Lecture. New approaches to the pathology and genetics of neurodegeneration |
| Q51371177 | AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease. |
| Q37075304 | Aberrant expression of myeloperoxidase in astrocytes promotes phospholipid oxidation and memory deficits in a mouse model of Alzheimer disease |
| Q31021996 | Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma |
| Q35156471 | Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention |
| Q48939525 | Absence of detectable IL-1beta production in murine prion disease: a model of chronic neurodegeneration. |
| Q48606558 | Accumulation of heparan sulfate proteoglycans in cerebellar senile plaques. |
| Q35833354 | Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer's disease. |
| Q42435307 | Acetyl-L-carnitine arginine amide prevents beta 25-35-induced neurotoxicity in cerebellar granule cells |
| Q38737086 | Acetylcholinesterase-Abeta complexes are more toxic than Abeta fibrils in rat hippocampus: effect on rat beta-amyloid aggregation, laminin expression, reactive astrocytosis, and neuronal cell loss |
| Q48913487 | Activated caspase-3 expression in Alzheimer's and aged control brain: correlation with Alzheimer pathology. |
| Q38186705 | Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia |
| Q40040126 | Activation of cerebral cytokine gene expression and its correlation with onset of reactive astrocyte and acute-phase response gene expression in scrapie |
| Q45969414 | Activation of group III metabotropic glutamate receptor reduces intracellular calcium in beta-amyloid peptide [31-35]-treated cortical neurons. |
| Q48354068 | Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. |
| Q48250765 | Active beta-amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of beta-amyloid |
| Q36252648 | Acute and Chronic Sustained Hypoxia Do Not Substantially Regulate Amyloid-β Peptide Generation In Vivo |
| Q34540588 | Adiponectin is protective against oxidative stress induced cytotoxicity in amyloid-beta neurotoxicity |
| Q35738142 | Advances in recent patent and clinical trial drug development for Alzheimer's disease |
| Q34651971 | Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease |
| Q40460527 | Age- and peroxidative stress-related modifications of the cerebral enzymatic activities linked to mitochondria and the glutathione system |
| Q37596042 | Age-Related Decline in Brain and Hepatic Clearance of Amyloid-Beta is Rectified by the Cholinesterase Inhibitors Donepezil and Rivastigmine in Rats |
| Q30418974 | Age-related changes in signal transduction. Implications for neuronal transmission and potential for drug intervention |
| Q43813693 | Age-related changes in the localization of presenilin-1 in cynomolgus monkey brain |
| Q48182902 | Age-related changes of Alzheimer’s disease-associated proteins in cynomolgus monkey brains |
| Q40398616 | Age-related fibrillar deposits in brains of C57BL/6 mice. A review of localization, staining characteristics, and strain specificity. |
| Q40660453 | Age-related fibrillar material in mouse brain. Assessing its potential as a biomarker of aging and as a model of human neurodegenerative disease |
| Q78170975 | Aged garlic extract attenuates the cytotoxicity of beta-amyloid on undifferentiated PC12 cells |
| Q74151866 | Aged garlic extract suppresses lipid peroxidation induced by beta-amyloid in PC12 cells |
| Q22253180 | Agrin binds to beta-amyloid (Abeta), accelerates abeta fibril formation, and is localized to Abeta deposits in Alzheimer's disease brain |
| Q35787956 | Agrin is a major heparan sulfate proteoglycan accumulating in Alzheimer's disease brain. |
| Q73024904 | Alpha 1-antichymotrypsin gene polymorphism and risk for Alzheimer's disease |
| Q30488155 | Alpha-helix targeting reduces amyloid-beta peptide toxicity |
| Q35244090 | Alpha1-chimaerin, a Rac1 GTPase-activating protein, is expressed at reduced mRNA levels in the brain of Alzheimer's disease patients |
| Q28191605 | Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization |
| Q48522129 | Altered distribution of the gangliosides GM1 and GM2 in Alzheimer's disease. |
| Q44266485 | Alternate aggregation pathways of the Alzheimer beta-amyloid peptide: Abeta association kinetics at endosomal pH. |
| Q27001223 | Alternative neural circuitry that might be impaired in the development of Alzheimer disease |
| Q91781242 | Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric Aβ and Tau Species |
| Q36105614 | Alzheimer Lesions in the Autopsied Brains of People 30 to 50 Years of Age |
| Q53200140 | Alzheimer amyloid beta-peptides exhibit ionophore-like properties in human erythrocytes. |
| Q34534448 | Alzheimer and beta-amyloid-treated fibroblasts demonstrate a decrease in a memory-associated GTP-binding protein, Cp20 |
| Q37603746 | Alzheimer beta/A4 amyloid precursor protein in human brain: aging-associated increases in holoprotein and in a proteolytic fragment |
| Q41650138 | Alzheimer beta/A4-amyloid precursor protein: evidence for putative amyloidogenic fragment |
| Q28262806 | Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum |
| Q36535484 | Alzheimer disease and platelets: how's that relevant |
| Q36410134 | Alzheimer disease and the prion disorders amyloid beta-protein and prion protein amyloidoses |
| Q30415581 | Alzheimer disease: a tale of two prions |
| Q26778149 | Alzheimer's Disease: Mechanism and Approach to Cell Therapy |
| Q33971270 | Alzheimer's amyloid fibrils: structure and assembly |
| Q53343627 | Alzheimer's and prion diseases: PDK1 at the crossroads. |
| Q38163914 | Alzheimer's as a metabolic disease |
| Q77787274 | Alzheimer's disease |
| Q33906977 | Alzheimer's disease amyloid beta-protein forms Zn(2+)-sensitive, cation-selective channels across excised membrane patches from hypothalamic neurons |
| Q35855587 | Alzheimer's disease and the amyloid cascade hypothesis: a critical review |
| Q37180713 | Alzheimer's disease clinical and research update for health care practitioners |
| Q35841706 | Alzheimer's disease is a vasocognopathy: a new term to describe its nature |
| Q36631376 | Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice |
| Q37195665 | Alzheimer's disease-associated mutations increase amyloid precursor protein resistance to γ-secretase cleavage and the Aβ42/Aβ40 ratio |
| Q45199955 | Alzheimer's disease. In search of the soluble |
| Q46084123 | Alzheimer's disease. In the beginning... |
| Q34954180 | Alzheimer's disease: the amyloid hypothesis and the Inverse Warburg effect |
| Q53210316 | Alzheimer's syndrome, not Alzheimer's disease. |
| Q47280353 | Alzheimer-Like Pattern of Hypometabolism Emerges with Elevated Amyloid-β Burden in Down Syndrome |
| Q33180485 | Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice |
| Q91905486 | Amelioration of Alzheimer's disease pathology and cognitive deficits by immunomodulatory agents in animal models of Alzheimer's disease |
| Q46109204 | Amino-terminal Deletions Enhance Aggregation of β-Amyloid Peptides in Vitro |
| Q34646469 | Ammonia and Alzheimer's disease |
| Q51127983 | Amorphous protein aggregation monitored using fluorescence self-quenching. |
| Q47095823 | Amylin Enhances Amyloid-β Peptide Brain to Blood Efflux Across the Blood-Brain Barrier |
| Q47990795 | Amyloid Beta monomers regulate cyclic adenosine monophosphate response element binding protein functions by activating type-1 insulin-like growth factor receptors in neuronal cells |
| Q24292067 | Amyloid beta binds trimers as well as monomers of the 75-kDa neurotrophin receptor and activates receptor signaling |
| Q77601661 | Amyloid beta peptide is not a candidate for the neurotrophic activities released from chromaffin cells |
| Q35773873 | Amyloid beta protein deposition in normal aging has the same characteristics as that in Alzheimer's disease. Predominance of A beta 42(43) and association of A beta 40 with cored plaques |
| Q35063341 | Amyloid beta-mediated cell death of cultured hippocampal neurons reveals extensive Tau fragmentation without increased full-length tau phosphorylation |
| Q42436428 | Amyloid beta-peptide 25-35 reduces [3H]acetylcholine release in retinal neurons. Involvement of metabolic dysfunction |
| Q71971013 | Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation |
| Q36099893 | Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NFkappaB-dependent mechanism |
| Q36317817 | Amyloid beta-protein as a substrate interacts with extracellular matrix to promote neurite outgrowth |
| Q24653927 | Amyloid beta-protein monomer folding: free-energy surfaces reveal alloform-specific differences |
| Q34083143 | Amyloid beta-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins |
| Q48842302 | Amyloid deposition is associated with c-Jun expression in Alzheimer's disease and amyloid angiopathy. |
| Q35019570 | Amyloid fibril proteins |
| Q28742804 | Amyloid oligomer neurotoxicity, calcium dysregulation, and lipid rafts |
| Q37690818 | Amyloid oligomers: spectroscopic characterization of amyloidogenic protein states. |
| Q58719037 | Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE) |
| Q39420600 | Amyloid precursor protein and tau transgenic models of Alzheimer‘s disease: insights from the past and directions for the future |
| Q52545476 | Amyloid precursor protein family-induced neuronal death is mediated by impairment of the neuroprotective calcium/calmodulin protein kinase IV-dependent signaling pathway. |
| Q92916846 | Amyloid β oligomers constrict human capillaries in Alzheimer's disease via signaling to pericytes |
| Q44653062 | Amyloid β protein deposition and neuron loss in osteopetrotic (op/op) mice |
| Q58135346 | Amyloid β-protein precursor and apolipoprotein E production in cultured cerebral endothelial cells isolated from brains of patients with neurodegenerative disorders at autopsy |
| Q35186126 | Amyloid β/A4 Precursor Protein (APP) Processing in Lysosomesa |
| Q37442426 | Amyloid-beta expression in retrosplenial cortex of triple transgenic mice: relationship to cholinergic axonal afferents from medial septum |
| Q48456362 | Amyloid-beta peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. |
| Q48788933 | Amyloid-beta proteins activate Ca(2+)-permeable channels through calcium-sensing receptors. |
| Q42058603 | Amyloid-β forms fibrils by nucleated conformational conversion of oligomers |
| Q57168692 | Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure |
| Q31088092 | Amyloid-β metabolism in Niemann-Pick C disease models and patients |
| Q91526804 | Amyloid-β-independent regulators of tau pathology in Alzheimer disease |
| Q43839169 | Amyloidogenic processing of human amyloid precursor protein in hippocampal neurons devoid of cathepsin D. |
| Q90631601 | Amyloids: Regulators of Metal Homeostasis in the Synapse |
| Q46838942 | An improved capillary electrophoresis method for in vitro monitoring of the challenging early steps of Aβ1-42 peptide oligomerization: application to anti-Alzheimer's drug discovery. |
| Q54127664 | An improved method of preparing the amyloid beta-protein for fibrillogenesis and neurotoxicity experiments. |
| Q33800962 | An update on the amyloid hypothesis |
| Q38268518 | An updated patent review of calpain inhibitors (2012 - 2014). |
| Q42488752 | Analysis of the 5'-flanking region of the beta-amyloid precursor protein gene that contributes to increased promoter activity in differentiated neuronal cells |
| Q51066935 | Analytical model and multiscale simulations of Aβ peptide aggregation in lipid membranes: towards a unifying description of conformational transitions, oligomerization and membrane damage. |
| Q44071719 | Annexin 5 and apolipoprotein E2 protect against Alzheimer's amyloid-beta-peptide cytotoxicity by competitive inhibition at a common phosphatidylserine interaction site |
| Q36731538 | Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. |
| Q51037995 | Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative. |
| Q42523894 | Antiamnesic effects of azaindolizinone derivative ZSET845 on impaired learning and decreased ChAT activity induced by amyloid-beta 25-35 in the rat. |
| Q34210015 | Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target |
| Q34229659 | Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3 |
| Q42987047 | Apolipoprotein E forms stable complexes with recombinant Alzheimer's disease beta-amyloid precursor protein |
| Q37117670 | Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons |
| Q40983052 | Apolipoprotein E. Structure, function, and possible roles in Alzheimer's disease |
| Q30497417 | Apolipoprotein E4 causes age- and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice |
| Q40571686 | Apolipoprotein E4 domain interaction occurs in living neuronal cells as determined by fluorescence resonance energy transfer |
| Q43559135 | Apolipoprotein E4 stimulates sulfation of glycosaminoglycans in neural cells |
| Q64979665 | Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer's disease. |
| Q22248076 | Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease |
| Q36501389 | Apoptosis is induced by beta-amyloid in cultured central nervous system neurons |
| Q47719854 | Apoptosis of cerebellar granule cells induced by serum withdrawal, glutamate or beta-amyloid, is independent of Jun kinase or p38 mitogen activated protein kinase activation. |
| Q41741254 | Apoptosis, neurotrophic factors and neurodegeneration |
| Q40957115 | Applications of gene therapy to the CNS. |
| Q40263720 | Archaeal proteasomes effectively degrade aggregation-prone proteins and reduce cellular toxicities in mammalian cells |
| Q44795710 | Architecture of the Alzheimer's A beta P ion channel pore |
| Q37961852 | Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease? |
| Q41735606 | Arisugacins, selective acetylcholinesterase inhibitors of microbial origin |
| Q46076651 | Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis |
| Q35188314 | Assembly and interrogation of Alzheimer's disease genetic networks reveal novel regulators of progression |
| Q92059193 | Assessing the therapeutic potential of Graptopetalum paraguayense on Alzheimer's disease using patient iPSC-derived neurons |
| Q48662691 | Association between naturally occurring anti-amyloid β autoantibodies and medial temporal lobe atrophy in Alzheimer's disease. |
| Q44410484 | Astrocytes accumulate Aβ42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains |
| Q33608918 | Astroglial heme oxygenase-1 and the origin of corpora amylacea in aging and degenerating neural tissues |
| Q40621541 | Astroglial regulation of apolipoprotein E expression in neuronal cells. Implications for Alzheimer's disease |
| Q38185153 | Atomic force microscopy to study molecular mechanisms of amyloid fibril formation and toxicity in Alzheimer's disease. |
| Q53352144 | Aβ dimers differ from monomers in structural propensity, aggregation paths and population of synaptotoxic assemblies. |
| Q42620803 | Aβ internalization by neurons and glia |
| Q42053390 | Aβ42 oligomers modulate β-secretase through an XBP-1s-dependent pathway involving HRD1. |
| Q50943210 | BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides. |
| Q93152965 | BACE1 Translation: At the Crossroads Between Alzheimer's Disease Neurodegeneration and Memory Consolidation |
| Q28480522 | BACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous system |
| Q44020743 | BACE1 interacts with nicastrin |
| Q38945980 | BRI2 ectodomain affects Aβ42 fibrillation and tau truncation in human neuroblastoma cells. |
| Q50546707 | Bacterial inclusion bodies of Alzheimer's disease β-amyloid peptides can be employed to study native-like aggregation intermediate states. |
| Q36089364 | Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease |
| Q37462091 | Beneficial effects of increased lysozyme levels in Alzheimer's disease modelled in Drosophila melanogaster |
| Q36989218 | Beta-amyloid modulation of synaptic transmission and plasticity |
| Q48171425 | Beta-amyloid peptide fragment 31-35 induces apoptosis in cultured cortical neurons |
| Q40668554 | Beta-amyloid peptide potentiates inflammatory responses induced by lipopolysaccharide, interferon -gamma and 'advanced glycation endproducts' in a murine microglia cell line |
| Q35065815 | Beta-amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease |
| Q48473428 | Beta-amyloid(Phe(SO3H)24)25-35 in rat nucleus basalis induces behavioral dysfunctions, impairs learning and memory and disrupts cortical cholinergic innervation. |
| Q46566282 | Beta-amyloid-induced reactive astrocytes display altered ability to support dendrite and axon growth from mouse cerebral cortical neurons in vitro |
| Q38532709 | Biflavonoids as Potential Small Molecule Therapeutics for Alzheimer's Disease |
| Q48357991 | Binding of amyloid beta-protein to intracellular brain proteins in rat and human. |
| Q37374362 | Binding of beta-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimer's disease. |
| Q34662682 | Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease |
| Q33292558 | Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life |
| Q45295140 | Biochemical, ultrastructural, and reversibility studies on huntingtin filaments isolated from mouse and human brain. |
| Q40779580 | Biologically active domain of the secreted form of the amyloid beta/A4 protein precursor |
| Q37755075 | Biomarker potential of heme oxygenase-1 in Alzheimer's disease and mild cognitive impairment |
| Q26739671 | Brain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in Humans |
| Q41061833 | Brain amyloid--a physicochemical perspective |
| Q39475937 | Brain microstructure reveals early abnormalities more than two years prior to clinical progression from mild cognitive impairment to Alzheimer's disease |
| Q41061846 | Brain parenchymal and microvascular amyloid in Alzheimer's disease |
| Q40912777 | C terminus of presenilin is required for overproduction of amyloidogenic Abeta42 through stabilization and endoproteolysis of presenilin |
| Q92947589 | C-Terminal Plays as the Possible Nucleation of the Self-Aggregation of the S-Shape Aβ11-42 Tetramer in Solution: Intensive MD Study |
| Q36517962 | C-terminal turn stability determines assembly differences between Aβ40 and Aβ42 |
| Q36370903 | CD36 mediates the innate host response to beta-amyloid |
| Q34017180 | CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic mice |
| Q37837903 | CSF biomarkers in neurodegenerative diseases. |
| Q37464182 | Calcium dyshomeostasis and neurotoxicity of Alzheimer's beta-amyloid protein |
| Q33862507 | Calcium ions promote formation of amyloid β-peptide (1-40) oligomers causally implicated in neuronal toxicity of Alzheimer's disease |
| Q37688886 | Can Alzheimer disease be prevented by amyloid-beta immunotherapy? |
| Q30458465 | Can zebrafish be used as animal model to study Alzheimer's disease? |
| Q64963501 | Canine Cognitive Dysfunction and Alzheimer’s Disease – Two Facets of the Same Disease? |
| Q48202887 | Canine counterpart of senile dementia of the Alzheimer type: amyloid plaques near capillaries but lack of spatial relationship with activated microglia and macrophages |
| Q47985863 | Capsaicin Attenuates Amyloid-β-Induced Synapse Loss and Cognitive Impairments in Mice |
| Q37683429 | Capturing a reactive state of amyloid aggregates: NMR-based characterization of copper-bound Alzheimer disease amyloid β-fibrils in a redox cycle |
| Q28376425 | Carbachol blocks beta-amyloid fragment 31-35-induced apoptosis in cultured cortical neurons |
| Q35978742 | Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice |
| Q36536417 | Catalytically active tissue transglutaminase colocalises with Aβ pathology in Alzheimer's disease mouse models |
| Q40410864 | Cathepsin B Improves ß-Amyloidosis and Learning and Memory in Models of Alzheimer's Disease. |
| Q50750468 | Cellular MTT reduction distinguishes the mechanism of action of beta-amyloid from that of tachykinin receptor peptides. |
| Q36706726 | Cellular ageing of Alzheimer's disease and down syndrome cells in culture |
| Q53199812 | Cellular and substrate adhesion molecules (integrins) and their ligands in cerebral amyloid plaques in Alzheimer's disease. |
| Q33740154 | Cellular mechanisms of beta-amyloid production and secretion |
| Q37348049 | Cellular stress response, sirtuins and UCP proteins in Alzheimer disease: role of vitagenes |
| Q43862569 | Cerebellar diffuse amyloid plaques are derived from dendritic Abeta42 accumulations in Purkinje cells |
| Q48108889 | Cerebral amyloid induces aberrant axonal sprouting and ectopic terminal formation in amyloid precursor protein transgenic mice |
| Q37211768 | Cerebral arachidonate cascade in dementia: Alzheimer's disease and vascular dementia |
| Q21129234 | Cerebral hemodynamics of the aging brain: risk of Alzheimer disease and benefit of aerobic exercise |
| Q39432592 | Cerebrospinal Fluid Biomarkers in Alzheimer's Disease-From Brain Starch to Bench and Bedside |
| Q90356067 | Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy |
| Q34196576 | Cerebrospinal fluid β-amyloid and tau are not associated with risk of delirium: a prospective cohort study in older adults with hip fracture. |
| Q37714992 | Chapter 5 - Development of iron chelator-nanoparticle conjugates as potential therapeutic agents for Alzheimer disease |
| Q37025521 | Characteristics of tau oligomers |
| Q41502302 | Characterization of 3D Voronoi tessellation nearest neighbor lipid shells provides atomistic lipid disruption profile of protein containing lipid membranes. |
| Q46182538 | Characterization of Aβ aggregation mechanism probed by congo red. |
| Q53318965 | Characterization of AβpN3 deposition in the brains of dogs of various ages and other animal species. |
| Q40972124 | Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer's disease. |
| Q34652305 | Characterization of a single-chain variable fragment recognizing a linear epitope of aβ: a biotechnical tool for studies on Alzheimer's disease? |
| Q35277863 | Characterization of alternative routes for processing of the Alzheimer beta/A4-amyloid precursor protein. Differential effects of phorbol esters and chloroquine |
| Q48495532 | Characterization of neuronal dystrophy induced by fibrillar amyloid beta: implications for Alzheimer's disease. |
| Q52525502 | Characterization of the interactions of Alzheimer beta-amyloid peptides with phospholipid membranes. |
| Q38817593 | Charge dependent retardation of amyloid β aggregation by hydrophilic proteins |
| Q35681844 | Chasing genes in Alzheimer's and Parkinson's disease |
| Q41865462 | Cholesterol modulates the interaction of beta-amyloid peptide with lipid bilayers |
| Q42751126 | Cholesterol-dependent energy transfer between fluorescent proteins-insights into protein proximity of APP and BACE1 in different membranes in Niemann-Pick type C disease cells. |
| Q33792493 | Choline acetyltransferase: the structure, distribution and pathologic changes in the central nervous system |
| Q77636721 | Cholinergic agonists increase intracellular Ca2+ in cultured human microglia |
| Q48669955 | Chronic Cerebral Hypoperfusion Accelerates Alzheimer's Disease Pathology with Cerebrovascular Remodeling in a Novel Mouse Model. |
| Q42452339 | Chronic neuroinflammation in rats reproduces components of the neurobiology of Alzheimer's disease |
| Q37442265 | Cited references and Medical Subject Headings (MeSH) as two different knowledge representations: clustering and mappings at the paper level |
| Q40670501 | Clinical approaches to dementia. |
| Q22241380 | Clinical immunologic approaches for the treatment of Alzheimer's disease |
| Q92450851 | Clinical trials of new drugs for Alzheimer disease |
| Q36139267 | Coexistence of phases in a protein heterodimer |
| Q42280027 | Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau. |
| Q52215410 | Cognitive deficits in asymptomatic first-degree relatives of Alzheimer's disease patients. |
| Q27309969 | Colloids as mobile substrates for the implantation and integration of differentiated neurons into the mammalian brain |
| Q48352514 | Colocalization of cholinesterases with beta amyloid protein in aged and Alzheimer's brains. |
| Q58477374 | Common variants of ACE contribute to variable age-at-onset of Alzheimer’s disease |
| Q34657052 | Comparative studies of disordered proteins with similar sequences: application to Aβ40 and Aβ42 |
| Q37262889 | Complement activation by beta-amyloid in Alzheimer disease |
| Q30665205 | Complement component C3 and complement receptor type 3 contribute to the phagocytosis and clearance of fibrillar Aβ by microglia |
| Q59505885 | Complement neoantigen and vitronectin are components of plaques in amyloid AL neuropathy |
| Q30665192 | Complement receptor 3 (CD11b/CD18) is implicated in the elimination of β-amyloid peptides |
| Q28474363 | Complete phenotypic recovery of an Alzheimer's disease model by a quinone-tryptophan hybrid aggregation inhibitor |
| Q35101970 | Computational drug repositioning through heterogeneous network clustering |
| Q28550499 | Conformational Dynamics and Binding Free Energies of Inhibitors of BACE-1: From the Perspective of Protonation Equilibria |
| Q33936728 | Conformational transition of amyloid beta-peptide |
| Q26773114 | Connectivity of Pathology: The Olfactory System as a Model for Network-Driven Mechanisms of Alzheimer's Disease Pathogenesis |
| Q39051111 | Consecutive Analysis of BACE1 Function on Developing and Developed Neuronal Cells. |
| Q89977186 | Contributions of DNA Damage to Alzheimer's Disease |
| Q39004687 | Control of Adhesion GPCR Function Through Proteolytic Processing |
| Q44485942 | Coordination abilities of the 1-16 and 1-28 fragments of beta-amyloid peptide towards copper(II) ions: a combined potentiometric and spectroscopic study |
| Q44136290 | Coordination of copper(II) ions by the 11-20 and 11-28 fragments of human and mouse beta-amyloid peptide |
| Q34479110 | Correlation of copper interaction, copper-driven aggregation, and copper-driven h(2)o(2) formation with aβ40 conformation |
| Q39314484 | Cross talk between neurometals and amyloidogenic proteins at the synapse and the pathogenesis of neurodegenerative diseases |
| Q53206490 | Cross-linking of a synthetic partial-length (1-28) peptide of the Alzheimer beta/A4 amyloid protein by transglutaminase. |
| Q35675578 | Curcumin Improves Amyloid β-Peptide (1-42) Induced Spatial Memory Deficits through BDNF-ERK Signaling Pathway |
| Q48339072 | Curcumin regulates insulin pathways and glucose metabolism in the brains of APPswe/PS1dE9 mice. |
| Q34222721 | Current and emerging drug treatment options for Alzheimer's disease: a systematic review. |
| Q37876893 | Current perspectives on potential role of albumin in neuroprotection. |
| Q33871345 | Current status on Alzheimer disease molecular genetics: from past, to present, to future |
| Q37737296 | Current therapeutic targets for the treatment of Alzheimer's disease |
| Q52655671 | Cu²⁺ accentuates distinct misfolding of Aβ₁₋₄₀ and Aβ₁₋₄₂ peptides, and potentiates membrane disruption. |
| Q34580289 | Cyclopamine modulates γ-secretase-mediated cleavage of amyloid precursor protein by altering its subcellular trafficking and lysosomal degradation |
| Q39739201 | Cystatin C protects neuronal cells from amyloid-beta-induced toxicity |
| Q48566884 | Cytochrome oxidase in Alzheimer's disease: biochemical, histochemical, and immunohistochemical analyses of the visual and other systems. |
| Q35155275 | Cytokines and inflammatory proteins in alzheimer's disease |
| Q90472727 | DNA methylation analysis on purified neurons and glia dissects age and Alzheimer's disease-specific changes in the human cortex |
| Q53231816 | DNA strand breaks in Alzheimer's disease. |
| Q40074162 | DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease |
| Q91938420 | Decoding the Role of Platelets and Related MicroRNAs in Aging and Neurodegenerative Disorders |
| Q57944931 | Dehydration stability of amyloid fibrils studied by AFM |
| Q28595059 | Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease |
| Q104459061 | Delta-secretase triggers Alzheimer's disease pathologies in wild-type hAPP/hMAPT double transgenic mice |
| Q37970511 | Dementia, stroke, and vascular risk factors; a review |
| Q89234809 | Dependence of the Formation of Tau and Aβ Peptide Mixed Aggregates on the Secondary Structure of the N-Terminal Region of Aβ |
| Q43905949 | Deposits of Amyloid β Protein in the Central Nervous System of Transgenic Mice |
| Q30700035 | Design and characterization of a membrane permeable N-methyl amino acid-containing peptide that inhibits Abeta1-40 fibrillogenesis |
| Q34082529 | Design, synthesis, and biological evaluation of novel fluorinated ethanolamines. |
| Q37960496 | Detection of Soluble Amyloid-β Oligomers and Insoluble High-Molecular-Weight Particles in CSF: Development of Methods with Potential for Diagnosis and Therapy Monitoring of Alzheimer's Disease |
| Q48335276 | Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's disease brain |
| Q42059881 | Determining the critical nucleus and mechanism of fibril elongation of the Alzheimer's Abeta(1-40) peptide. |
| Q33979228 | Development and validation of a yeast high-throughput screen for inhibitors of Aβ₄₂ oligomerization |
| Q28728851 | Development of a small D-enantiomeric Alzheimer's amyloid-β binding peptide ligand for future in vivo imaging applications |
| Q37519725 | Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease |
| Q48697017 | Developmental and aging changes in the expression of amyloid precursor protein in Down syndrome brains. |
| Q26750648 | Diabetes Mellitus Induces Alzheimer's Disease Pathology: Histopathological Evidence from Animal Models |
| Q37665855 | Differential contribution of APP metabolites to early cognitive deficits in a TgCRND8 mouse model of Alzheimer's disease |
| Q92217505 | Differential effects of Down's syndrome and Alzheimer's neuropathology on default mode connectivity |
| Q44084109 | Disassembly of amyloid beta-protein fibril by basement membrane components |
| Q36298522 | Discovery and structure activity relationship of small molecule inhibitors of toxic β-amyloid-42 fibril formation |
| Q35842197 | Disordered binding of small molecules to Aβ(12-28). |
| Q34173686 | Displacement currents associated with the insertion of Alzheimer disease amyloid beta-peptide into planar bilayer membranes |
| Q38163821 | Disruption of zinc homeostasis and the pathogenesis of senile dementia |
| Q37043088 | Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology |
| Q48535367 | Distribution of Alzheimer's disease amyloid protein precursor in normal human and rat nervous system |
| Q36202381 | Distribution of Misfolded Prion Protein Seeding Activity Alone Does Not Predict Regions of Neurodegeneration |
| Q36512770 | Diurnal variations in salivary protein carbonyl levels in normal and cognitively impaired human subjects |
| Q38899753 | Docosahexaenoic acid: one molecule diverse functions. |
| Q38863885 | Does the MK2-dependent Production of TNFα Regulate mGluR-dependent Synaptic Plasticity? |
| Q40561527 | Dorothy Russell Memorial Lecture. The molecular pathology of Alzheimer's disease: are we any closer to understanding the neurodegenerative process? |
| Q91707000 | Dreaming of a New World Where Alzheimer's Is a Treatable Disorder |
| Q38331415 | Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. |
| Q92966000 | Dynamical decoration of stabilized-microtubules by Tau-proteins |
| Q42475459 | Early and rapid de novo synthesis of Alzheimer beta A4-amyloid precursor protein (APP) in activated microglia. |
| Q48949634 | Effect of 17-beta-estradiol and ginsenoside Rg1 on reactive microglia induced by beta-amyloid peptides. |
| Q40909157 | Effect of Aged Garlic Extract on the Cytotoxicity of Alzheimer β-Amyloid Peptide in Neuronal PC12 Cells |
| Q35110540 | Effect of C-terminal residues of Aβ on copper binding affinity, structural conversion and aggregation |
| Q41452871 | Effect of ionophores on the processing of the beta-amyloid precursor protein in different cell lines |
| Q44314293 | Effect of melatonin on changes in locomotor activity rhythm of Syrian hamsters injected with beta amyloid peptide 25-35 in the suprachiasmatic nuclei |
| Q53406038 | Effect of pathogenic mutations on the structure and dynamics of Alzheimer's A beta 42-amyloid oligomers. |
| Q35028555 | Effect of protein kinase A inhibitors on the production of Abeta40 and Abeta42 by human cells expressing normal and Alzheimer's disease-linked mutated betaAPP and presenilin 1. |
| Q86630312 | Effect of the antioxidant action of Ginkgo biloba extract (EGb 761) on aging and oxidative stress |
| Q41346587 | Effects of Aβ exposure on long-term associative memory and its neuronal mechanisms in a defined neuronal network |
| Q28361095 | Effects of S-2474, a novel nonsteroidal anti-inflammatory drug, on amyloid beta protein-induced neuronal cell death |
| Q43685887 | Effects of aluminum on the neurotoxicity of primary cultured neurons and on the aggregation of beta-amyloid protein |
| Q42498874 | Effects of amyloid-beta-(25-35) on passive avoidance, radial-arm maze learning and choline acetyltransferase activity in the rat. |
| Q48348428 | Effects of chronic chlorpromazine or lithium administration on ageing-related lipopigment in rat Purkinje neurones. |
| Q34059086 | Effects of collagen-induced rheumatoid arthritis on amyloidosis and microvascular pathology in APP/PS1 mice. |
| Q52036902 | Effects of doses of fragment (25-35) of beta-amyloid peptide on behavior in rats. |
| Q44182568 | Effects of endothelin B receptor agonists on amyloid beta protein (25-35)-induced neuronal cell death |
| Q53234106 | Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer's disease amyloid fibrils by microglia. |
| Q34146163 | Effects of ligands on unfolding of the amyloid β-peptide central helix: mechanistic insights from molecular dynamics simulations |
| Q31113633 | Effects of membrane interaction and aggregation of amyloid β-peptide on lipid mobility and membrane domain structure |
| Q36012311 | Effects of peptides derived from terminal modifications of the aβ central hydrophobic core on aβ fibrillization |
| Q42124387 | Effects of polyamino acids and polyelectrolytes on amyloid β fibril formation |
| Q53179441 | Effects of sulfate ions on Alzheimer beta/A4 peptide assemblies: implications for amyloid fibril-proteoglycan interactions |
| Q44654104 | Effects of β-amyloid protein on serotoninergic, noradrenergic, and cholinergic markers in neurons of the pontomesencephalic tegmentum in the rat |
| Q36998748 | Efficacy of SPI-1865, a novel gamma-secretase modulator, in multiple rodent models |
| Q44597512 | Efficient inhibition of β‐secretase gene expression in HEK293 cells by tRNAVal‐driven and CTE‐helicase associated hammerhead ribozymes |
| Q44658826 | Electrophoretic mobility of Alzheimer’s amyloid-β peptides in urea–sodium dodecyl sulfate–polyacrylamide gel electrophoresis |
| Q28293094 | Elevated adenosine monophosphate deaminase activity in Alzheimer's disease brain |
| Q45874593 | Emerging roles of ER stress in the etiology and pathogenesis of Alzheimer's disease |
| Q35218171 | Encompassing receptor flexibility in virtual screening using ensemble docking-based hybrid QSAR: discovery of novel phytochemicals for BACE1 inhibition. |
| Q37687314 | Endothelial nitric oxide: protector of a healthy mind |
| Q48915342 | Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and a "humanized" Abeta sequence. |
| Q44111429 | Enhanced antidepressant effect of sigma(1) (sigma(1)) receptor agonists in beta(25-35)-amyloid peptide-treated mice |
| Q36473320 | Enhanced antigen retrieval of amyloid β immunohistochemistry: re-evaluation of amyloid β pathology in Alzheimer disease and its mouse model |
| Q48211401 | Enhancement of amyloid beta 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer's disease |
| Q34361613 | Enhancement of pheochromocytoma nerve cell growth by consecutive fractionization of Angelica gigas Nakai extracts |
| Q43619959 | Entactin-induced inhibition of human amyloid beta-protein fibril formation in vitro |
| Q48387207 | Estradiol prevents Aβ 25 35-inhibited long-term potentiation induction through enhancing survival of newborn neurons in the dentate gyrus. |
| Q61455053 | Evaluate neuroprotective effect of silibinin using chronic unpredictable stress (cus) model |
| Q30424327 | Evidence for Cu(I) clusters and Zn(II) clusters in neuronal growth-inhibitory factor isolated from bovine brain |
| Q37285389 | Evidence of endothelial dysfunction in the development of Alzheimer's disease: Is Alzheimer's a vascular disorder? |
| Q35782389 | Evidence of neuronal oxidative damage in Alzheimer's disease. |
| Q32028060 | Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease |
| Q35026216 | Examination of the role of endopeptidase 3.4.24.15 in A beta secretion by human transfected cells. |
| Q37716769 | Exosomes in the Diseased Brain: First Insights from In vivo Studies |
| Q90319075 | Expression analysis of beta-secretase 1 (BACE1) enzyme in peripheral blood of patients with Alzheimer's disease |
| Q37122175 | Expression and processing of fluorescent fusion proteins of amyloid precursor protein (APP). |
| Q37173085 | Expression and purification of amyloid-beta peptides from Escherichia coli |
| Q48586574 | Expression of alpha-synuclein, the precursor of non-amyloid beta component of Alzheimer's disease amyloid, in human cerebral blood vessels. |
| Q36707304 | Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain |
| Q48487509 | Expression of hexokinase mRNA in human hippocampus. |
| Q41712816 | Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. |
| Q90654387 | First evaluation of PET-based human biodistribution and radiation dosimetry of 11C-BU99008, a tracer for imaging the imidazoline2 binding site |
| Q27676370 | Flexibility of the flap in the active site of BACE1 as revealed by crystal structures and molecular dynamics simulations |
| Q87360290 | Formation of a flavin-linked peptide |
| Q38663636 | Four Decades of Research in Alzheimer's Disease (1975-2014): A Bibliometric and Scientometric Analysis |
| Q40882405 | Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of beta-amyloid peptide |
| Q35782745 | Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. |
| Q41039991 | GABAergic deafferentation hypothesis of brain aging and Alzheimer's disease; pharmacologic profile of the benzodiazepine antagonist, flumazenil |
| Q30497475 | GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice |
| Q37836722 | Galanin acts as a trophic factor to the central and peripheral nervous systems. |
| Q43300789 | Ganglioside-induced amyloid formation by human islet amyloid polypeptide in lipid rafts |
| Q37126036 | Gd-nanoparticles functionalization with specific peptides for ß-amyloid plaques targeting |
| Q37740141 | Gelsolin as therapeutic target in Alzheimer's disease |
| Q24308258 | Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain |
| Q34881830 | Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene |
| Q41133936 | Generation of Alzheimer amyloid beta peptide through nonspecific proteolysis |
| Q74244462 | Generation of aggregated beta-amyloid in the rat hippocampus impairs synaptic transmission and plasticity and causes memory deficits |
| Q31078263 | Generation of anti-beta-amyloid antibodies via phage display technology |
| Q92414622 | Genetic background modifies CNS-mediated sensorimotor decline in the AD-BXD mouse model of genetic diversity in Alzheimer's disease |
| Q53116855 | Genome instability in Alzheimer disease. |
| Q60935279 | Genomics: New Light on Alzheimer's Disease Research |
| Q48672915 | Ginsenoside Rb1 regulates ChAT, NGF and trkA mRNA expression in the rat brain. |
| Q24676445 | Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1 |
| Q48277713 | Glial fibrillary acidic protein is necessary for mature astrocytes to react to beta-amyloid |
| Q64981930 | Glutamate receptor delocalization in postsynaptic membrane and reduced hippocampal synaptic plasticity in the early stage of Alzheimer's disease. |
| Q89356189 | Glycation affects fibril formation of Aβ peptides |
| Q36961152 | Heat shock proteins and amateur chaperones in amyloid-Beta accumulation and clearance in Alzheimer's disease |
| Q37766494 | Heme oxygenase-1 in Alzheimer disease: a tribute to Moussa Youdim |
| Q35183966 | Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders |
| Q33734278 | Hereditary cerebral haemorrhage with amyloidosis, Dutch type (HCHWA-D): clinicopathological studies |
| Q40785335 | Heterogeneity in Alzheimer's disease |
| Q31271197 | High affinity binding of monoclonal antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation |
| Q35833986 | High tissue content of soluble beta 1-40 is linked to cerebral amyloid angiopathy |
| Q35813445 | High-resolution NMR characterization of low abundance oligomers of amyloid-β without purification |
| Q33732756 | High-resolution bioelectrical imaging of Aβ-induced network dysfunction on CMOS-MEAs for neurotoxicity and rescue studies. |
| Q48238987 | Highly efficient solid phase supported radiosynthesis of [11 C]PiB using tC18 cartridge as a "3-in-1" production entity |
| Q92131798 | Hippocampal Deficits in Amyloid-β-Related Rodent Models of Alzheimer's Disease |
| Q90862831 | History and progress of hypotheses and clinical trials for Alzheimer's disease |
| Q64239061 | How stress mediators can cumulatively contribute to Alzheimer's disease An allostatic load approach |
| Q98293049 | Human Serum Albumin-Inspired Glycopeptide-Based Multifunctional Inhibitor of Amyloid-β Toxicity |
| Q30442882 | Human antibodies reactive with beta-amyloid protein in Alzheimer's disease |
| Q33355985 | Human microglial cells synthesize albumin in brain |
| Q37263277 | Human microtubule-associated-protein tau regulates the number of protofilaments in microtubules: a synchrotron x-ray scattering study. |
| Q37649577 | Humanin and the receptors for humanin |
| Q48236550 | Humanin peptides block calcium influx of rat hippocampal neurons by altering fibrogenesis of Abeta(1-40). |
| Q100385903 | Hyaluronan-carnosine conjugates inhibit Aβ aggregation and toxicity |
| Q35093638 | Hydrogen sulfide inhibits A2A adenosine receptor agonist induced β-amyloid production in SH-SY5Y neuroblastoma cells via a cAMP dependent pathway. |
| Q89977785 | Hyperthermia Induced by Near-Infrared Laser-Irradiated CsWO3 Nanoparticles Disintegrates Preformed Lysozyme Amyloid Fibrils |
| Q38247021 | IRS2 integrates insulin/IGF1 signalling with metabolism, neurodegeneration and longevity |
| Q51311651 | Identification and structural characterisation of carboxy-terminal polypeptides and antibody epitopes of Alzheimer's amyloid precursor protein using high-resolution mass spectrometry. |
| Q61798662 | Identification of Pre-symptomatic Gene Signatures That Predict Resilience to Cognitive Decline in the Genetically Diverse AD-BXD Model |
| Q58188403 | Identification of full length β-amyloid precursor protein in human neuronal and non-neuronal cell culture supernatant: a possible extracellular source for the generation of Aβ |
| Q26770766 | Imaging Multimodalities for Dissecting Alzheimer's Disease: Advanced Technologies of Positron Emission Tomography and Fluorescence Imaging |
| Q42653687 | Imaging Vascular Disease and Amyloid in the Aging Brain: Implications for Treatment |
| Q38187861 | Immunogenicity of DNA- and recombinant protein-based Alzheimer disease epitope vaccines |
| Q36790089 | Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial |
| Q28281534 | Immunohistochemical and in situ analysis of amyloid precursor-like protein-1 and amyloid precursor-like protein-2 expression in Alzheimer disease and aged control brains |
| Q48946243 | Immunohistochemical characteristics of the constituents of senile plaques and amyloid angiopathy in aged cynomolgus monkeys. |
| Q43568858 | Immunohistochemical investigation of the brain of aged dogs. I. Detection of neurofibrillary tangles and of 4-hydroxynonenal protein, an oxidative damage product, in senile plaques |
| Q35040852 | Immunological approaches as therapy for Alzheimer's disease |
| Q58765987 | Implications of Metal Binding and Asparagine Deamidation for Amyloid Formation |
| Q36748573 | In Vivo Amyloid-β Imaging in the APPPS1-21 Transgenic Mouse Model with a (89)Zr-Labeled Monoclonal Antibody |
| Q36729084 | In Vivo Characterization of a Novel γ-Secretase Inhibitor SCH 697466 in Rodents and Investigation of Strategies for Managing Notch-Related Side Effects |
| Q33826249 | In silico theoretical molecular modeling for Alzheimer's disease: the nicotine-curcumin paradigm in neuroprotection and neurotherapy |
| Q52196702 | In vitro aggregation facilities beta-amyloid peptide-(25-35)-induced amnesia in the rat. |
| Q28363291 | In vitro studies of amyloid beta-protein fibril assembly and toxicity provide clues to the aetiology of Flemish variant (Ala692-->Gly) Alzheimer's disease |
| Q35638734 | Increase of synaptic density and memory retention by a peptide representing the trophic domain of the amyloid beta/A4 protein precursor |
| Q38312630 | Increased amoeboid microglial density in the olfactory bulb of Parkinson's and Alzheimer's patients |
| Q40523596 | Increased tau phosphorylation in apolipoprotein E4 transgenic mice is associated with activation of extracellular signal-regulated kinase: modulation by zinc |
| Q39529635 | Influence of scan duration on the accuracy of β-amyloid PET with florbetaben in patients with Alzheimer's disease and healthy volunteers |
| Q55613035 | Inhaled Xenon Washout as a Biomarker of Alzheimer's Disease. |
| Q44495064 | Inhibition of Abeta production and APP maturation by a specific PKA inhibitor |
| Q35052504 | Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of beta-amyloid-mediated cell death |
| Q31571122 | Inhibition of inducible nitric oxide synthase gene expression by indomethacin or ibuprofen in beta-amyloid protein-stimulated J774 cells |
| Q42174365 | Inhibitory effects of NAMI-A-like ruthenium complexes on prion neuropeptide fibril formation |
| Q44496212 | Insights into the molecular interactions between aminopeptidase and amyloid beta peptide using molecular modeling techniques. |
| Q41535127 | Insights into the role of the cholinergic component of the septohippocampal pathway: what have we learned from experimental lesion studies? |
| Q37696477 | Integrating metabolism and longevity through insulin and IGF1 signaling |
| Q37225357 | Integration of metabolism and inflammation by lipid-activated nuclear receptors |
| Q37702259 | Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall |
| Q36988218 | Interaction of ApoE3 and ApoE4 isoforms with an ITM2b/BRI2 mutation linked to the Alzheimer disease-like Danish dementia: Effects on learning and memory |
| Q42424729 | Interaction of the amyloid β peptide with sodium dodecyl sulfate as a membrane-mimicking detergent |
| Q28304287 | Interaction of the phosphotyrosine interaction/phosphotyrosine binding-related domains of Fe65 with wild-type and mutant Alzheimer's beta-amyloid precursor proteins |
| Q39599916 | Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. |
| Q40794411 | Intracellular calcium changes in neuronal cells induced by Alzheimer's beta-amyloid protein are blocked by estradiol and cholesterol |
| Q44433388 | Intracranially Administered Anti-Αβ Antibodies Reduce β-Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation |
| Q37905118 | Intraneuronal Aβ as a trigger for neuron loss: can this be translated into human pathology? |
| Q48476226 | Intraneuronal amyloid precursor protein (APP) and appearance of extracellular beta-amyloid peptide (abeta) in the brain of aging kokanee salmon. |
| Q34343432 | Introduction and expression of the 400 kilobase amyloid precursor protein gene in transgenic mice [corrected] |
| Q35009820 | Investigating interventions in Alzheimer's disease with computer simulation models |
| Q39797126 | Involvement of a disintegrin and metalloproteinase 10 and 17 in shedding of tumor necrosis factor-alpha |
| Q48531630 | Involvement of amyloid precursor protein in functional synapse formation in cultured hippocampal neurons. |
| Q44386828 | Involvement of calcineurin in the neurotoxic effects induced by amyloid-beta and prion peptides |
| Q50871872 | Involvement of α7 nAChR signaling cascade in epigallocatechin gallate suppression of β-amyloid-induced apoptotic cortical neuronal insults. |
| Q41041853 | Ion channel hypothesis for Alzheimer amyloid peptide neurotoxicity |
| Q38851332 | Ion channel regulation by β-secretase BACE1 - enzymatic and non-enzymatic effects beyond Alzheimer's disease. |
| Q30908064 | Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics |
| Q40900244 | Is ammonia a pathogenetic factor in Alzheimer's disease? |
| Q30310306 | Is amyloid beta-peptide neurotoxic or neuroprotective and what is its role in the binding of metal ions? |
| Q37188315 | Is amyloid-β harmful to the brain? Insights from human imaging studies |
| Q38470218 | Is interaction of amyloid β-peptides with metals involved in cognitive activity? |
| Q53216116 | Isoform-specific binding of human apolipoprotein E to the non-amyloid beta component of Alzheimer's disease amyloid. |
| Q37432185 | Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from Alzheimer disease brains. |
| Q48396205 | La lunga attesa: towards a molecular approach to neuroimaging and therapeutics in Alzheimer's disease. |
| Q33960315 | Lack of LDL receptor enhances amyloid deposition and decreases glial response in an Alzheimer's disease mouse model |
| Q45132090 | Laminin and its neurite outgrowth-promoting domain in the brain in Alzheimer's disease and Down's syndrome patients |
| Q37833589 | Lectin-affinity chromatography brain glycoproteomics and Alzheimer disease: insights into protein alterations consistent with the pathology and progression of this dementing disorder |
| Q51731717 | Length-dependent manifestation of vibration mode regulates a specific intermediate morphology of Aβ17-42 in different environments. |
| Q36082628 | Lessons from a Rare Familial Dementia: Amyloid and Beyond |
| Q48765862 | Levels of cerebrospinal fluid apolipoprotein E in patients with Alzheimer's disease and healthy controls. |
| Q52365744 | Ligand field molecular dynamics simulation of Pt(II)-phenanthroline binding to N-terminal fragment of amyloid-β peptide. |
| Q41861075 | Light and electron microscopic localization of beta-amyloid protein in muscle biopsies of patients with inclusion-body myositis |
| Q38741714 | Limitations of the hCMEC/D3 cell line as a model for Aβ clearance by the human blood-brain barrier. |
| Q28307760 | Link between Aluminum and the Pathogenesis of Alzheimer's Disease: The Integration of the Aluminum and Amyloid Cascade Hypotheses |
| Q24649564 | Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice |
| Q38101013 | Liver X receptors, nervous system, and lipid metabolism. |
| Q40781493 | Loss of hippocampal serine protease BSP1/neuropsin predisposes to global seizure activity. |
| Q34274025 | Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid β-peptide elimination from the brain |
| Q34903445 | Macromolecular crowding as a suppressor of human IAPP fibril formation and cytotoxicity |
| Q38063413 | Making the brain glow: in vivo bioluminescence imaging to study neurodegeneration |
| Q42552479 | Mannose-binding lectin binds to amyloid β protein and modulates inflammation |
| Q42425724 | Measurement of the attachment and assembly of small amyloid-β oligomers on live cell membranes at physiological concentrations using single-molecule tools. |
| Q31052453 | Mechanism of accelerated assembly of beta-amyloid filaments into fibrils by KLVFFK(6). |
| Q34311672 | Mechanism of fiber assembly: treatment of Aβ peptide aggregation with a coarse-grained united-residue force field |
| Q73066485 | Mechanism of interleukin-1- and tumor necrosis factor alpha-dependent regulation of the alpha 1-antichymotrypsin gene in human astrocytes |
| Q34993154 | Medicinal chemistry approaches for the treatment and prevention of Alzheimer's disease |
| Q35603692 | Medicinal value of asiaticoside for Alzheimer's disease as assessed using single-molecule-detection fluorescence correlation spectroscopy, laser-scanning microscopy, transmission electron microscopy, and in silico docking. |
| Q24672231 | Medin: an integral fragment of aortic smooth muscle cell-produced lactadherin forms the most common human amyloid |
| Q34180157 | Melatonin Potentiates the Neuroprotective Properties of Resveratrol Against Beta-Amyloid-Induced Neurodegeneration by Modulating AMP-Activated Protein Kinase Pathways |
| Q48237622 | Melatonin ameliorates amyloid beta-induced memory deficits, tau hyperphosphorylation and neurodegeneration via PI3/Akt/GSk3β pathway in the mouse hippocampus |
| Q54262422 | Memantine may affect pseudobulbar affect in patients with Alzheimer's disease. |
| Q34923956 | Membrane Incorporation, Channel Formation, and Disruption of Calcium Homeostasis by Alzheimer's β-Amyloid Protein |
| Q40443903 | Membrane alterations as causes of impaired signal transduction in Alzheimer's disease and aging |
| Q37896721 | Membrane and surface interactions of Alzheimer's Aβ peptide--insights into the mechanism of cytotoxicity |
| Q53323047 | Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity. |
| Q33568378 | Membrane localization of beta-amyloid 1-42 in lysosomes: a possible mechanism for lysosome labilization |
| Q41454656 | Membrane phospholipid alterations in Alzheimer's disease: deficiency of ethanolamine plasmalogens |
| Q30912577 | MicroRNA expression in Alzheimer blood mononuclear cells |
| Q48933977 | Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. |
| Q37224694 | Microscopic investigation of reversible nanoscale surface size dependent protein conjugation |
| Q37729567 | Microsecond molecular dynamics simulation of Aβ42 and identification of a novel dual inhibitor of Aβ42 aggregation and BACE1 activity |
| Q27027319 | Mild cognitive impairment. Part 2: Biological markers for diagnosis and prediction of dementia in Alzheimer's disease |
| Q46386102 | Mitochondrial involvement in memory impairment induced by scopolamine in rats |
| Q34508624 | Modeling Alzheimer's disease in transgenic rats |
| Q38374439 | Modulation in the conformational and stability attributes of the Alzheimer's disease associated amyloid-beta mutants and their favorable stabilization by curcumin: molecular dynamics simulation analysis |
| Q35927997 | Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine. |
| Q26776031 | Molecular Targets in Alzheimer's Disease: From Pathogenesis to Therapeutics |
| Q45233550 | Molecular determinants of the interaction between the C-terminal domain of Alzheimer's beta-amyloid peptide and apolipoprotein E alpha-helices |
| Q92465649 | Molecular dynamics simulations of copper binding to amyloid-β Glu22 mutants |
| Q38267422 | Molecular dynamics simulations reveal the protective role of cholesterol in β-amyloid protein-induced membrane disruptions in neuronal membrane mimics |
| Q38636134 | Molecular insights into Aβ42 protofibril destabilization with a fluorinated compound D744: A molecular dynamics simulation study. |
| Q34117380 | Molecular mechanism of neurodegeneration induced by Alzheimer's beta-amyloid protein: channel formation and disruption of calcium homeostasis |
| Q53317865 | Monitoring the aggregation processes of amyloid-β using a spin-labeled, fluorescent nitroxyl radical. |
| Q48404840 | Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer's disease: a postmortem study. |
| Q38809649 | Monoaminergic neuropathology in Alzheimer's disease |
| Q33630090 | Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide |
| Q41579457 | Monomer-dependent secondary nucleation in amyloid formation |
| Q48325307 | Morphologically distinct types of amyloid plaques point the way to a better understanding of Alzheimer's disease pathogenesis |
| Q42367176 | Multi-target-directed phenol-triazole ligands as therapeutic agents for Alzheimer's disease |
| Q58701999 | Multimodal neuroimaging study of cerebrovascular disease, amyloid deposition, and neurodegeneration in Alzheimer's disease progression |
| Q48150230 | Multiple Ligands Targeting Cholinesterases and β-Amyloid: Synthesis, Biological Evaluation of Heterodimeric Compounds with Benzylamine Pharmacophore |
| Q34450675 | Multivariate analyses of amyloid-beta oligomer populations indicate a connection between pore formation and cytotoxicity |
| Q41422671 | Murine models of brain aging and age-related neurodegenerative diseases |
| Q67484385 | Mutation in codon 713 of the β amyloid precursor protein gene presenting with schizophrenia |
| Q55306359 | Mutations in the β-amyloid precursor protein in familial Alzheimer's disease increase Aβ oligomer production in cellular models. |
| Q31085628 | Mutations that reduce aggregation of the Alzheimer's Abeta42 peptide: an unbiased search for the sequence determinants of Abeta amyloidogenesis |
| Q32046799 | N-terminal EFRH sequence of Alzheimer's beta-amyloid peptide represents the epitope of its anti-aggregating antibodies |
| Q37485472 | N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody |
| Q42262002 | NADPH Oxidase Mediates β-Amyloid Peptide-Induced Neuronal Death in Mouse Cortical Cultures |
| Q40014779 | NFkappaB-dependent control of BACE1 promoter transactivation by Abeta42. |
| Q44164029 | NMR and CD studies on the interaction of Alzheimer beta-amyloid peptide (12-28) with beta-cyclodextrin |
| Q38110699 | Nanomaterials for reducing amyloid cytotoxicity |
| Q33957213 | Nanoparticle delivery of transition-metal chelators to the brain: Oxidative stress will never see it coming! |
| Q37195646 | Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease |
| Q38647131 | Nanoparticulate flurbiprofen reduces amyloid-β42 generation in an in vitro blood-brain barrier model |
| Q37396583 | Nanoscale assembly in biological systems: from neuronal cytoskeletal proteins to curvature stabilizing lipids |
| Q41828490 | Nanoscopic and photonic ultrastructural characterization of two distinct insulin amyloid states. |
| Q48240233 | Nanostructural Differentiation and Toxicity of Amyloid-β25-35 Aggregates Ensue from Distinct Secondary Conformation. |
| Q38130176 | Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases |
| Q41748072 | Natural Product and Natural Product-Derived Gamma Secretase Modulators from Actaea Racemosa Extracts |
| Q29614851 | Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function |
| Q39144600 | Neural stem cell therapy for neurodegenerative disorders: The role of neurotrophic support. |
| Q36347323 | Neural stem cell transplantation at critical period improves learning and memory through restoring synaptic impairment in Alzheimer's disease mouse model |
| Q64863760 | Neuritic sprouting with aberrant expression of the nitric oxide synthase III gene in neurodegenerative diseases |
| Q38202910 | Neuroinflammation in Alzheimer's disease: from pathogenesis to a therapeutic target |
| Q43184034 | Neuroinflammation is not a Prerequisite for Diabetes-induced Tau Phosphorylation |
| Q44795511 | Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. |
| Q38379006 | Neuronal hyperactivity--A key defect in Alzheimer's disease? |
| Q33955154 | Neuronal response to physical injury and its relationship to the pathology of Alzheimer's disease |
| Q40232590 | Neuropathological changes in brain cortex and hippocampus in a rat model of Alzheimer's disease. |
| Q53137703 | Neuropathology of Alzheimer's disease. |
| Q53237947 | Neuropeptides in hippocampus and cortex in transgenic mice overexpressing V717F beta-amyloid precursor protein--initial observations. |
| Q33809078 | Neuroprotective approaches in experimental models of beta-amyloid neurotoxicity: relevance to Alzheimer's disease |
| Q46941559 | Neuroprotective effect of a chuk-me-sun-dan on neurons from ischemic damage and neuronal cell toxicity |
| Q38455834 | Neuroprotective effect of edible brown alga Eisenia bicyclis on amyloid beta peptide-induced toxicity in PC12 cells |
| Q58096533 | Neuroprotective effect of naturally occurring RXR agonists isolated from Sophora tonkinensis Gagnep. on amyloid-β-induced cytotoxicity in PC12 cells |
| Q42718263 | Neuroprotective effects of Rosa damascena extract on learning and memory in a rat model of amyloid-β-induced Alzheimer's disease |
| Q36836759 | Neurosteroids block the increase in intracellular calcium level induced by Alzheimer’s β-amyloid protein in long-term cultured rat hippocampal neurons. |
| Q38023860 | Neurotoxicity of amyloid β-protein: synaptic and network dysfunction |
| Q40917126 | Neurotrophic factor deprivation-induced death |
| Q93051573 | New Insights Into the Pathogenesis of Alzheimer's Disease |
| Q64072741 | Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer's disease |
| Q48534404 | Non-plaque dystrophic dendrites in Alzheimer hippocampus: a new pathological structure revealed by glutamate receptor immunocytochemistry. |
| Q41331992 | Non-uniform self-assembly: On the anisotropic architecture of α-synuclein supra-fibrillar aggregates. |
| Q52044284 | Nontoxic amyloid beta peptide 1-42 suppresses acetylcholine synthesis. Possible role in cholinergic dysfunction in Alzheimer's disease. |
| Q41526761 | Normal cellular processing of the beta-amyloid precursor protein results in the secretion of the amyloid beta peptide and related molecules |
| Q49599472 | Novel botanical drug DA-9803 prevents deficits in Alzheimer's mouse models. |
| Q38127470 | Novel disease-modifying therapeutics for the treatment of Alzheimer's disease. |
| Q77508966 | Novel domain-specific actions of amyloid precursor protein on developing synapses |
| Q40418259 | Novel functions of cholinesterases in development, physiology and disease |
| Q37012066 | Novel strategies for Alzheimer's disease treatment |
| Q89187503 | Novel therapies for combating chronic neuropathological sequelae of TBI |
| Q30389386 | Nucleus factory on cavitation bubble for amyloid β fibril |
| Q38536860 | Obesity and Aging: Consequences for Cognition, Brain Structure, and Brain Function |
| Q53073171 | Oil Palm Phenolics Inhibit the In Vitro Aggregation of β-Amyloid Peptide into Oligomeric Complexes. |
| Q34631952 | Oleuropein aglycone protects transgenic C. elegans strains expressing Aβ42 by reducing plaque load and motor deficit |
| Q42563174 | On the stability of the soluble amyloid aggregates |
| Q48502816 | Oncostatin M and the interleukin-6 and soluble interleukin-6 receptor complex regulate alpha1-antichymotrypsin expression in human cortical astrocytes. |
| Q28396730 | Oncostatin M promotes excitotoxicity by inhibiting glutamate uptake in astrocytes: implications in HIV-associated neurotoxicity |
| Q37736146 | Opening up the DNA methylome of dementia |
| Q35166985 | Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice |
| Q39906670 | Optical and SPION-enhanced MR imaging shows that trans-stilbene inhibitors of NF-κB concomitantly lower Alzheimer's disease plaque formation and microglial activation in AβPP/PS-1 transgenic mouse brain. |
| Q36012385 | Oral treatment with the d-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer's Disease transgenic mice |
| Q35793436 | Osmotin attenuates amyloid beta-induced memory impairment, tau phosphorylation and neurodegeneration in the mouse hippocampus |
| Q38680244 | Osmotin-loaded magnetic nanoparticles with electromagnetic guidance for the treatment of Alzheimer's disease. |
| Q45870914 | Overexpression of glutathione peroxidase increases the resistance of neuronal cells to Abeta-mediated neurotoxicity |
| Q34297526 | Overexpression of pyruvate dehydrogenase kinase 1 and lactate dehydrogenase A in nerve cells confers resistance to amyloid β and other toxins by decreasing mitochondrial respiration and reactive oxygen species production. |
| Q26749061 | Overview of Alzheimer's Disease and Some Therapeutic Approaches Targeting Aβ by Using Several Synthetic and Herbal Compounds |
| Q48604084 | Oxidative modification of glutamine synthetase by amyloid beta peptide. |
| Q46272723 | Oxidative stress and the amyloid beta peptide in Alzheimer's disease |
| Q36851164 | Oxysterols, cholesterol homeostasis, and Alzheimer disease |
| Q41108776 | P53 Dysfunction in Neurodegenerative Diseases - The Cause or Effect of Pathological Changes? |
| Q64085399 | Pathogenic tau modifications occur in axons before the somatodendritic compartment in mossy fiber and Schaffer collateral pathways |
| Q90585698 | Pathological Continuum From the Rise in Pulse Pressure to Impaired Neurovascular Coupling and Cognitive Decline |
| Q34491870 | Pathophysiological Roles of Cyclooxygenases and Prostaglandins in the Central Nervous System |
| Q38205782 | Pathways to Alzheimer's disease |
| Q34124260 | Peptides for therapy and diagnosis of Alzheimer's disease |
| Q42776392 | Periodontitis and Alzheimer's Disease: A Possible Comorbidity between Oral Chronic Inflammatory Condition and Neuroinflammation. |
| Q37947768 | Pharmacological treatment of Alzheimer disease |
| Q42655716 | Phase II clinical trials of anti-amyloid β antibodies: When is enough, enough? |
| Q44239767 | Phosphatidylinositol and PI-4-monophosphate recover amyloid beta protein-induced inhibition of Cl- -ATPase activity |
| Q34718043 | Phosphorylation of amyloid precursor protein (APP) at Thr668 regulates the nuclear translocation of the APP intracellular domain and induces neurodegeneration |
| Q24675701 | Phosphorylation of presenilin-2 regulates its cleavage by caspases and retards progression of apoptosis |
| Q46535530 | Physiological regulation of the beta-amyloid precursor protein signaling domain by c-Jun N-terminal kinase JNK3 during neuronal differentiation. |
| Q35852763 | Physiological roles of amyloid-beta and implications for its removal in Alzheimer's disease |
| Q86199455 | Phytomedicines as potential inhibitors of β amyloid aggregation: significance to Alzheimer's disease |
| Q37424112 | Placenta-derived mesenchymal stem cells improve memory dysfunction in an Aβ1-42-infused mouse model of Alzheimer's disease |
| Q36509219 | Plaque-Associated Local Toxicity Increases over the Clinical Course of Alzheimer Disease |
| Q64064010 | Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease |
| Q34424794 | Plasma ß-amyloid and cognitive decline |
| Q48715103 | Platelets contribute to amyloid-β aggregation in cerebral vessels through integrin αIIbβ3-induced outside-in signaling and clusterin release. |
| Q58138243 | Platelets from patients with Alzheimer's disease or other dementias exhibit disease-specific and apolipoprotein E correlatable defects |
| Q35058548 | Polarized secretion of beta-amyloid precursor protein and amyloid beta-peptide in MDCK cells |
| Q36517139 | Potassium channel dysfunction in fibroblasts identifies patients with Alzheimer disease |
| Q58842921 | Potential therapeutic targets for Alzheimer’s disease |
| Q39626472 | Pre-aggregated Aβ1-42 peptide increases tau aggregation and hyperphosphorylation after short-term application |
| Q37035851 | Precision Modulation of Neurodegenerative Disease-Related Gene Expression in Human iPSC-Derived Neurons. |
| Q53025487 | Preclinical Comparison of the Amyloid-β Radioligands [(11)C]Pittsburgh compound B and [(18)F]florbetaben in Aged APPPS1-21 and BRI1-42 Mouse Models of Cerebral Amyloidosis. |
| Q92135579 | Precursor-Independent Overproduction of Beta-Amyloid in AD: Mitochondrial Dysfunction as Possible Initiator of Asymmetric RNA-Dependent βAPP mRNA Amplification. An Engine that Drives Alzheimer's Disease |
| Q46669801 | Predicting the in vitro toxicity of synthetic beta-amyloid (1-40). |
| Q44593239 | Preincubation with atrial natriuretic peptide protects NG108-15 cells against the toxic/proapoptotic effects of the nitric oxide donor S -nitroso- N -acetylpenicillamine |
| Q89052841 | Preparation of Pure Populations of Amyloid β-Protein Oligomers of Defined Size |
| Q46201444 | Preparation of amyloid beta-protein for structural and functional studies |
| Q49744153 | Preparation of stable amyloid β-protein oligomers of defined assembly order. |
| Q34649249 | Presenile dementia syndromes: an update on taxonomy and diagnosis |
| Q30531717 | Presenilin deficiency or lysosomal inhibition enhances Wnt signaling through relocalization of GSK3 to the late-endosomal compartment. |
| Q44778037 | Presenilin-2 in the cynomolgus monkey brain: investigation of age-related changes |
| Q37099368 | Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer's disease |
| Q34412262 | Prionics or the kinetic basis of prion diseases |
| Q35691850 | Probing structural features of Alzheimer's amyloid-β pores in bilayers using site-specific amino acid substitutions |
| Q72659608 | Production of the Alzheimer's beta-amyloid peptide by C6 glioma cells |
| Q46529938 | Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. |
| Q43725989 | Progressive brain dysfunction following intracerebroventricular infusion of beta(1-42)-amyloid peptide |
| Q53203171 | Proline-directed and non-proline-directed phosphorylation of PHF-tau. |
| Q40305548 | Protease nexin-2/amyloid beta-protein precursor: a cerebral anticoagulant? |
| Q33244612 | Protective effects of compound FLZ on beta-amyloid peptide-(25-35)-induced mouse hippocampal injury and learning and memory impairment |
| Q41873080 | Protective effects of luteolin against cognitive impairment induced by infusion of Aβ peptide in rats. |
| Q48915656 | Protective effects of prescription n-3 fatty acids against impairment of spatial cognitive learning ability in amyloid β-infused rats. |
| Q34572391 | Protective mechanisms by cystatin C in neurodegenerative diseases |
| Q34471876 | Protein fragments: functional and structural roles of their coevolution networks |
| Q37785102 | Protein oxidative modifications in the ageing brain: consequence for the onset of neurodegenerative disease |
| Q35564758 | Protein phosphorylation and APP metabolism |
| Q92949118 | Protein-Capped Metal Nanoparticles Inhibit Tau Aggregation in Alzheimer's Disease |
| Q90172885 | Protein-Encoding RNA-to-RNA Information Transfer in Mammalian Cells: Principles of RNA-Dependent mRNA Amplification |
| Q92416204 | Protein-based amide proton transfer-weighted MR imaging of amnestic mild cognitive impairment |
| Q48379496 | Proteins immunologically related to erythrocyte anion transporter band 3 are altered in brain areas affected by Alzheimer's disease. |
| Q53220824 | Proteolysis of Alzheimer's disease beta-amyloid precursor protein by factor Xa. |
| Q28477446 | Proteomic identification of protein targets for 15-deoxy-Δ(12,14)-prostaglandin J2 in neuronal plasma membrane |
| Q35773733 | Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease |
| Q42219743 | Purification and characterization of the human γ-secretase activating protein |
| Q35186152 | Purification and cloning of brain proteases capable of degrading the beta-amyloid precursor protein |
| Q24292869 | Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase |
| Q48311393 | Quantitative neuronal c-fos and c-jun expression in Alzheimer's disease |
| Q36451170 | Random forest-based similarity measures for multi-modal classification of Alzheimer's disease |
| Q58790854 | Rapid and reversible impairment of episodic memory by a high-fat diet in mice |
| Q50888807 | Rat's trick to escape Alzheimer's disease. |
| Q37438261 | Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy |
| Q35813037 | Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABAA potentiating activity for use in dementia |
| Q37187966 | Reassessing the amyloid cascade hypothesis of Alzheimer's disease |
| Q43227037 | Rebalancing β-Amyloid-Induced Decrease of ATP Level by Amorphous Nano/Micro Polyphosphate: Suppression of the Neurotoxic Effect of Amyloid β-Protein Fragment 25-35. |
| Q39145449 | Recent Progress in Alzheimer's Disease Research, Part 1: Pathology |
| Q40907186 | Recent research on the causes of Alzheimer's disease |
| Q38012858 | Reciprocal regulation of cholesterol and beta amyloid at the subcellular level in Alzheimer's disease |
| Q49310065 | Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease. |
| Q41829670 | Reduction in amyloid A amyloid formation in apolipoprotein-E-deficient mice |
| Q52030675 | Reduction in somatostatin and substance P levels and choline acetyltransferase activity in the cortex and hippocampus of the rat after chronic intracerebroventricular infusion of beta-amyloid (1-40). |
| Q24530141 | Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration |
| Q44157383 | Regulation of amyloid precursor protein (APP) phosphorylation and processing by p35/Cdk5 and p25/Cdk5. |
| Q37672243 | Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain |
| Q92550935 | Relationships Between Executive Control Circuit Activity, Amyloid Burden, and Education in Cognitively Healthy Older Adults |
| Q37739881 | Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition |
| Q35701937 | Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging |
| Q48051236 | Replica exchange molecular dynamics study of the truncated amyloid beta (11-40) trimer in solution. |
| Q55428413 | Results of Beta Secretase-Inhibitor Clinical Trials Support Amyloid Precursor Protein-Independent Generation of Beta Amyloid in Sporadic Alzheimer's Disease. |
| Q38792491 | Retromer and Rab2-dependent trafficking mediate PS1 degradation by proteasomes in endocytic disturbance |
| Q37060837 | Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide |
| Q28078442 | Risk factor SORL1: from genetic association to functional validation in Alzheimer's disease |
| Q37889475 | Risk profiles of Alzheimer disease |
| Q41835365 | Role of Notch-1 signaling pathway in PC12 cell apoptosis induced by amyloid beta-peptide (25-35) |
| Q36678091 | Role of P-glycoprotein in mediating rivastigmine effect on amyloid-β brain load and related pathology in Alzheimer's disease mouse model |
| Q41611893 | Role of aromatic side chains in amyloid β-protein aggregation |
| Q26830320 | Role of environmental contaminants in the etiology of Alzheimer's disease: a review |
| Q58562562 | Role of purinergic receptors in the Alzheimer's disease |
| Q33307872 | Role of the ubiquitin proteasome system in Alzheimer's disease |
| Q34372681 | Role of ubiquitin-proteasome-mediated proteolysis in nervous system disease |
| Q46019370 | Roles of apolipoprotein E4 (ApoE4) in the pathogenesis of Alzheimer's disease: lessons from ApoE mouse models. |
| Q60907691 | Royal jelly peptides: potential inhibitors of β-secretase in N2a/APP695swe cells |
| Q39242927 | SILAC-based proteomic analysis to investigate the impact of amyloid precursor protein expression in neuronal-like B103 cells |
| Q92691872 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PF-06751979, a Potent and Selective Oral BACE1 Inhibitor: Results from Phase I Studies in Healthy Adults and Healthy Older Subjects |
| Q41191851 | Salen-manganese complexes: combined superoxide dismutase/catalase mimics with broad pharmacological efficacy |
| Q41705451 | Scaling and alpha-helix regulation of protein relaxation in a lipid bilayer. |
| Q34375724 | Scavenger receptor class B type I (SR-BI) regulates perivascular macrophages and modifies amyloid pathology in an Alzheimer mouse model |
| Q50582495 | Schisandrin C Ameliorates Learning and Memory Deficits by Aβ1-42 -induced Oxidative Stress and Neurotoxicity in Mice. |
| Q36102657 | Schizandrin, an antioxidant lignan from Schisandra chinensis, ameliorates Aβ1-42-induced memory impairment in mice |
| Q41316757 | Seed-induced acceleration of amyloid-β mediated neurotoxicity in vivo |
| Q33202467 | Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice: digital morphometric analyses |
| Q37984548 | Selective vulnerability of synaptic signaling and metabolism to nitrosative stress |
| Q36634365 | Self-Assembly for the Synthesis of Functional Biomaterials |
| Q45360347 | Sendai virus vector-mediated brain-derived neurotrophic factor expression ameliorates memory deficits and synaptic degeneration in a transgenic mouse model of Alzheimer's disease |
| Q48212567 | Senile plaques do not progressively accumulate with normal aging |
| Q70856314 | Senile plaques in an aged two-humped (Bactrian) camel (Camelus bactrianus) |
| Q48212584 | Senile plaques in temporal lobe epilepsy. |
| Q33221066 | Sequence determinants of enhanced amyloidogenicity of Alzheimer A{beta}42 peptide relative to A{beta}40. |
| Q40779571 | Sequestration of amyloid beta-peptide |
| Q36413592 | Serotonin 6 receptor controls Alzheimer's disease and depression |
| Q53329775 | Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease. |
| Q53214597 | Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease. |
| Q58784650 | Sex: A Significant Risk Factor for Neurodevelopmental and Neurodegenerative Disorders |
| Q52040573 | Sigma1 (sigma 1) receptor agonists and neurosteroids attenuate B25-35-amyloid peptide-induced amnesia in mice through a common mechanism. |
| Q37336898 | Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases. |
| Q40095201 | Site-specific effects of peptide lipidation on beta-amyloid aggregation and cytotoxicity |
| Q47212309 | Size of neocortical neurons in control subjects and in Alzheimer's disease |
| Q53220157 | Slow degradation of aggregates of the Alzheimer's disease amyloid beta-protein by microglial cells. |
| Q48455427 | Small Aβ1-42 oligomer-induced membrane depolarization of neuronal and microglial cells: role of N-methyl-D-aspartate receptors. |
| Q48945409 | Small heat shock proteins induce a cerebral inflammatory reaction. |
| Q38003497 | Small-molecule BACE1 inhibitors: a patent literature review (2006 - 2011). |
| Q38083082 | Small-molecule inhibitors/modulators of amyloid-β peptide aggregation and toxicity for the treatment of Alzheimer's disease: a patent review (2010 - 2012). |
| Q47228947 | Snakes as veterinary emblems |
| Q44898893 | Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo |
| Q24645994 | Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior |
| Q28131750 | Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide |
| Q53275156 | Solution structure and dynamics of human metallothionein-3 (MT-3). |
| Q33263907 | Spatial relationship between synapse loss and beta-amyloid deposition in Tg2576 mice |
| Q48591309 | Specific association of small heat shock proteins with the pathological hallmarks of Alzheimer's disease brains. |
| Q48912106 | Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia. |
| Q36923099 | Specific mechanism for blood inflow stimulation in brain area prone to Alzheimer's disease lesions |
| Q44632561 | Spectroscopic investigation on gel‐forming β‐sheet assemblage of peptide derivatives |
| Q73561113 | Sporadic inclusion body myositis correlates with increased expression and cross-linking by transglutaminases 1 and 2 |
| Q52894494 | Starvation induces tau hyperphosphorylation in mouse brain: implications for Alzheimer's disease. |
| Q48132206 | Starvation triggers Abeta42 generation from human umbilical vascular endothelial cells |
| Q48547451 | Stimulating the Activity of Amyloid-Beta Degrading Enzymes: A Novel Approach for the Therapeutic Manipulation of Amyloid-Beta Levels. |
| Q48443000 | Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity. |
| Q89115776 | Store depletion-induced h-channel plasticity rescues a channelopathy linked to Alzheimer's disease |
| Q47758213 | Structural and kinetic features of amyloid beta-protein fibrillogenesis |
| Q36684459 | Structural model for the β-amyloid fibril based on interstrand alignment of an antiparallel-sheet comprising a C-terminal peptide |
| Q54144813 | Structural transitions associated with the interaction of Alzheimer beta-amyloid peptides with gangliosides. |
| Q47705414 | Structure and texture of fibrous crystals formed by Alzheimer's abeta(11-25) peptide fragment |
| Q33896874 | Structure determination of micelle-like intermediates in amyloid beta -protein fibril assembly by using small angle neutron scattering |
| Q92214816 | Structure of amyloid-β (20-34) with Alzheimer's-associated isomerization at Asp23 reveals a distinct protofilament interface |
| Q40900620 | Structure-activity relationship study of asiatic acid derivatives against beta amyloid (A beta)-induced neurotoxicity |
| Q41894180 | Structure-activity relationships in peptide modulators of β-amyloid protein aggregation: variation in α,α-disubstitution results in altered aggregate size and morphology |
| Q53320104 | Studies of the growth, evolution, and self-aggregation of β-amyloid fibrils using tapping-mode atomic force microscopy. |
| Q41987801 | Sulphated glycosaminoglycans prevent the neurotoxicity of a human prion protein fragment |
| Q41099684 | Superoxide free radical and intracellular calcium mediate A beta(1-42) induced endothelial toxicity. |
| Q73225313 | Suppressive action produced by beta-amyloid peptide fragment 31-35 on long-term potentiation in rat hippocampus is N-methyl-D-aspartate receptor-independent: it's offset by (-)huperzine A |
| Q34189782 | Surface behavior and lipid interaction of Alzheimer beta-amyloid peptide 1-42: a membrane-disrupting peptide |
| Q48456509 | Sympathetic neurite outgrowth is greater on plaque-poor vs. plaque-rich regions of Alzheimer's disease cryostat sections. |
| Q35834240 | Synaptic pathology and glial responses to neuronal injury precede the formation of senile plaques and amyloid deposits in the aging cerebral cortex |
| Q42686096 | Systemic administration of atipamezole, a selective antagonist of alpha-2 adrenoceptors, facilitates behavioural activity but does not influence short-term or long-term memory in trimethyltin-intoxicated and control rats |
| Q30527791 | Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice |
| Q41702367 | Systemic treatment with liver X receptor agonists raises apolipoprotein E, cholesterol, and amyloid-β peptides in the cerebral spinal fluid of rats |
| Q36080653 | TNFAIP1 contributes to the neurotoxicity induced by Aβ25-35 in Neuro2a cells |
| Q28304401 | TREM2 and the neuroimmunology of Alzheimer's disease |
| Q89726182 | TRPV1 activation alleviates cognitive and synaptic plasticity impairments through inhibiting AMPAR endocytosis in APP23/PS45 mouse model of Alzheimer's disease |
| Q38970893 | Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease |
| Q36235980 | Targeting protein aggregation for the treatment of degenerative diseases |
| Q39458294 | Testing the therapeutic potential of doxycycline in a Drosophila melanogaster model of Alzheimer disease |
| Q37239001 | The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias |
| Q21296650 | The Alzheimer's amyloid-degrading peptidase, neprilysin: can we control it? |
| Q33861122 | The Delta33-35 Mutant alpha-Domain Containing beta-Domain-Like M(3)S(9) Cluster Exhibits the Function of alpha-Domain with M(4)S(11) Cluster in Human Growth Inhibitory Factor |
| Q53236323 | The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. |
| Q33692255 | The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases |
| Q90433483 | The Impact of Natural Compounds on S-Shaped Aβ42 Fibril: From Molecular Docking to Biophysical Characterization |
| Q91733029 | The Molecular Basis for Apolipoprotein E4 as the Major Risk Factor for Late-Onset Alzheimer's Disease |
| Q47897788 | The Relationship of Brain Amyloid Load and APOE Status to Regional Cortical Thinning and Cognition in the ADNI Cohort |
| Q64968356 | The Role of Antibodies and Their Receptors in Protection Against Ordered Protein Assembly in Neurodegeneration. |
| Q57299999 | The Role of KLF in Alzheimer's Disease |
| Q29614972 | The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics |
| Q30668465 | The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy |
| Q26749528 | The amyloid hypothesis of Alzheimer's disease at 25 years |
| Q40779615 | The amyloid precursor protein in ischemic brain injury and chronic hypoperfusion |
| Q41603023 | The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor |
| Q48228764 | The antioxidant vitamin E modulates amyloid beta-peptide-induced creatine kinase activity inhibition and increased protein oxidation: implications for the free radical hypothesis of Alzheimer's disease |
| Q43210353 | The association of three BACE1 gene polymorphisms (exon5 C/G, intron 5 T/G and 3'UTR T/A) with sporadic Alzheimer's disease susceptibility: a meta-analysis |
| Q48274340 | The cellular pathology associated with Alzheimer beta-amyloid deposits in non-demented aged individuals |
| Q41364335 | The characteristics of astrocyte on Aβ clearance altered in Alzheimer's disease were reversed by anti-inflammatory agent (+)-2-(1-hydroxyl-4-oxocyclohexyl) ethyl caffeate |
| Q37152815 | The chemical neurobiology of carbohydrates |
| Q35599843 | The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain. |
| Q39068135 | The discovery of Alzheimer-causing mutations in the APP gene and the formulation of the "amyloid cascade hypothesis". |
| Q48202884 | The distribution of amyloid beta precursor protein in canine brain |
| Q44983531 | The effect of citalopram on gene expression profile of Alzheimer lymphocytes |
| Q53220261 | The effect of tacrine and leupeptin on the secretion of the beta-amyloid precursor protein in HeLa cells. |
| Q48130002 | The effects of chronic estradiol treatment on working memory deficits induced by combined infusion of beta-amyloid (1-42) and ibotenic acid |
| Q36349347 | The etiology of Alzheimer's disease: the pathogenesis of dementia. The role of neurotoxins |
| Q36466825 | The exosome secretory pathway transports amyloid precursor protein carboxyl-terminal fragments from the cell into the brain extracellular space |
| Q33803360 | The expression of apoptosis inducing factor (AIF) is associated with aging-related cell death in the cortex but not in the hippocampus in the TgCRND8 mouse model of Alzheimer's disease |
| Q48252938 | The expression of key oxidative stress-handling genes in different brain regions in Alzheimer's disease |
| Q48136460 | The expression of several mitochondrial and nuclear genes encoding the subunits of electron transport chain enzyme complexes, cytochrome c oxidase, and NADH dehydrogenase, in different brain regions in Alzheimer's disease |
| Q39215023 | The flavonoid derivative 2-(4' Benzyloxyphenyl)-3-hydroxy-chromen-4-one protects against Aβ42-induced neurodegeneration in transgenic Drosophila: insights from in silico and in vivo studies. |
| Q38204914 | The hairpin conformation of the amyloid β peptide is an important structural motif along the aggregation pathway |
| Q40807293 | The immunopathology of Alzheimer's disease and some related disorders |
| Q36767917 | The inverse association of cancer and Alzheimer's: a bioenergetic mechanism |
| Q35183605 | The involvement of astrocytes and an acute phase response in the amyloid deposition of Alzheimer's disease |
| Q35871043 | The levels of water-soluble and triton-soluble Aβ are increased in Alzheimer's disease brain |
| Q50009444 | The many guises of amyloidosis. |
| Q36799375 | The molecular mechanisms of the anti-amyloid effects of phenols |
| Q41062817 | The molecular significance of amyloid beta-peptide for Alzheimer's disease |
| Q34190161 | The multiple paradoxes of presenilins |
| Q38015342 | The neurotrophins and their role in Alzheimer's disease |
| Q45730801 | The number of cysteine residues per mole in apolipoprotein E affects systematically synchronous neural interactions in women's healthy brains. |
| Q35155272 | The participation of interleukin-6 in the pathogenesis of alzheimer's disease |
| Q34950366 | The polyphenol oleuropein aglycone protects TgCRND8 mice against Aß plaque pathology |
| Q33808415 | The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. |
| Q48638260 | The protective effect of Borago Officinalis extract on amyloid β (25-35)-induced long term potentiation disruption in the dentate gyrus of male rats. |
| Q39951771 | The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity |
| Q37474466 | The role and therapeutic targeting of α-, β- and γ-secretase in Alzheimer's disease |
| Q37830311 | The role of G protein-coupled receptors in the pathology of Alzheimer's disease |
| Q41624342 | The role of amyloid in the pathogenesis of Alzheimer's disease |
| Q34361424 | The role of astrocytes in axonal regeneration in the mammalian CNS. |
| Q37211751 | The role of beta-amyloid protein in synaptic function: implications for Alzheimer's disease therapy |
| Q34356970 | The sigma-1 receptor chaperone as an inter-organelle signaling modulator |
| Q46621202 | The synaptic Abeta hypothesis of Alzheimer disease |
| Q41828232 | The transcription factor XBP1 in memory and cognition: Implications in Alzheimer disease |
| Q39641837 | The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a {beta}-secretase-dependent pathway |
| Q57526641 | The treatment of Alzheimer's disease |
| Q41542810 | The triplet of lysine residues (Lys724-Lys725-Lys726) of Alzheimer's amyloid precursor protein plays an important role in membrane anchorage and processing |
| Q34018961 | Theoretical models of the ion channel structure of amyloid beta-protein |
| Q34014330 | Therapeutic approaches to Alzheimer's disease. |
| Q39137730 | Thermodynamically stable amyloid-β monomers have much lower membrane affinity than the small oligomers. |
| Q34023541 | Thrombin: a neuronal cell modulator |
| Q41653816 | Tissue Transglutaminase and Its Product Isopeptide Are Increased in Alzheimer's Disease and APPswe/PS1dE9 Double Transgenic Mice Brains |
| Q40822165 | Tissue transglutaminase-catalysed cross-linking induces Apolipoprotein E multimers inhibiting Apolipoprotein E's protective effects towards amyloid-beta-induced toxicity |
| Q37698330 | Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence? |
| Q50516465 | Toxicity of protein aggregates in PC12 cells: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. |
| Q34092740 | Transcranial near-infrared laser therapy applied to promote clinical recovery in acute and chronic neurodegenerative diseases. |
| Q48559540 | Transcriptional activation and increase in expression of Alzheimer's beta-amyloid precursor protein gene is mediated by TGF-beta in normal human astrocytes. |
| Q36381106 | Transcriptional alterations related to neuropathology and clinical manifestation of Alzheimer's disease. |
| Q74747006 | Transgenic mice and cytokine actions in the brain: bridging the gap between structural and functional neuropathology |
| Q40947107 | Transgenic mice and modeling Alzheimer's disease |
| Q33971296 | Transgenic mouse models of Alzheimer's disease |
| Q35700645 | Transthyretin sequesters amyloid beta protein and prevents amyloid formation |
| Q38960486 | Treatment of Alzheimer's Disease: The Legacy of the Cholinergic Hypothesis, Neuroplasticity, and Future Directions |
| Q37249765 | Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders |
| Q41656266 | Trophic effect of beta-amyloid precursor protein on cerebral cortical neurons in culture |
| Q42754605 | Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau. |
| Q34719716 | Two distinct amyloid beta-protein (Abeta) assembly pathways leading to oligomers and fibrils identified by combined fluorescence correlation spectroscopy, morphology, and toxicity analyses |
| Q41887513 | Two-way cleavage of β-amyloid protein precursor by multicatalytic proteinase |
| Q34763060 | USF binds to the APB alpha sequence in the promoter of the amyloid beta-protein precursor gene |
| Q64266957 | Ubiquitin binds the amyloid β peptide and interferes with its clearance pathways |
| Q33847868 | Unfolding of the amyloid β-peptide central helix: mechanistic insights from molecular dynamics simulations |
| Q48390009 | Upregulation of amyloid precursor protein gene promoter in rat primary hippocampal neurons by phorbol ester, IL-1 and retinoic acid, but not by reactive oxygen species. |
| Q51761107 | Use of Eflornithine (DFMO) in the Treatment of Early Alzheimer's Disease: A Compassionate Use, Single-Case Study. |
| Q47397920 | Using an NMR metabolomics approach to investigate the pathogenicity of amyloid-beta and alpha-synuclein |
| Q89596058 | Using human induced pluripotent stem cells (hiPSCs) to investigate the mechanisms by which Apolipoprotein E (APOE) contributes to Alzheimer's disease (AD) risk |
| Q37300264 | Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ40 and Aβ42 Peptides in Plasma |
| Q28546473 | Virtual and In Vitro Screens Reveal a Potential Pharmacophore that Avoids the Fibrillization of Aβ1-42 |
| Q39466630 | Visualization of co-localization in Aβ42-administered neuroblastoma cells reveals lysosome damage and autophagosome accumulation related to cell death |
| Q98290871 | West Nile Virus-Induced Neurologic Sequelae-Relationship to Neurodegenerative Cascades and Dementias |
| Q35773966 | Widespread neuronal expression of the presenilin-1 early-onset Alzheimer's disease gene in the murine brain |
| Q37032393 | Wnt-pathway activation during the early stage of neurodegeneration in FTDP-17 mice |
| Q37378620 | Yi-Zhi-Fang-Dai Formula Protects against Aβ1-42 Oligomer Induced Cell Damage via Increasing Hsp70 and Grp78 Expression in SH-SY5Y Cells |
| Q91819631 | Zinc transporters in Alzheimer's disease |
| Q47831358 | Zinc, Carnosine, and Neurodegenerative Diseases. |
| Q37725035 | Zn2+ interaction with Alzheimer amyloid beta protein calcium channels |
| Q40616509 | beta-Amyloid Ca(2+)-channel hypothesis for neuronal death in Alzheimer disease |
| Q48112949 | beta-Amyloid fragment 25-35 selectively decreases complex IV activity in isolated mitochondria |
| Q36636403 | beta-Amyloid precursor protein binds to the neurite-promoting IKVAV site of laminin |
| Q37691301 | beta-Amyloid toxicity in organotypic hippocampal cultures: protection by EUK-8, a synthetic catalytic free radical scavenger |
| Q24564120 | beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease |
| Q43627467 | beta-Amyloid-induced cytotoxicity, peroxide generation and blockade of glutamate uptake in cultured astrocytes |
| Q28376637 | beta-amyloid peptide-induced death of PC 12 cells and cerebellar granule cell neurons is inhibited by long-term lithium treatment |
| Q27300851 | iTRAQ analysis of complex proteome alterations in 3xTgAD Alzheimer's mice: understanding the interface between physiology and disease |
| Q35286237 | p53-dependent control of transactivation of the Pen2 promoter by presenilins |
| Q47860140 | p75 neurotrophin receptor interacts with and promotes BACE1 localization in endosomes aggravating amyloidogenesis. |
| Q46052685 | β-Amyloid stimulates glial cells in vitro to produce growth factors that accumulate in senile plaques in Alzheimer's disease |
| Q92258873 | β-Amyrin Ameliorates Alzheimer's Disease-Like Aberrant Synaptic Plasticity in the Mouse Hippocampus |
| Q40592264 | β-amyloid infusion into lateral ventricle alters behavioral thermoregulation and attenuates acquired heat tolerance in rats. |
| Q28245473 | β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease |
| Q92481832 | δ-secretase in neurodegenerative diseases: mechanisms, regulators and therapeutic opportunities |
Search more.